Group 1 - The company, Saily Medical, announced that its controlling shareholder, Saihai Technology, has pledged 3 million shares, bringing the total pledged shares to 17 million, which is 78.55% of Saihai's holdings and 8.09% of the total shares outstanding [1] - The actual controller, Mr. Wen Wei, holds approximately 9.63 million shares, representing 4.58% of the total shares, and has pledged 530,000 shares, which is 55.01% of his holdings and 2.52% of the total shares [1] - As of the announcement date, the total pledged shares by Saihai Technology and Mr. Wen Wei amount to 22.3 million, accounting for 71.3% of their combined holdings and 10.61% of the total shares outstanding [1] Group 2 - For the fiscal year 2024, Saily Medical's revenue composition is projected to be 97.09% from commercial activities and 2.91% from industrial activities [1] - The company's market capitalization is currently valued at 6.6 billion yuan [2]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 10.30%（截至 2025 年 8 月 20 日总股 本，下同）。近日，赛海科技将其中 3,000,000 股股份办理了质押登记手续。本 次质押手续办理完毕后，赛海科技累计质押公司股份 17,000,000 股，占其持有 公司股份比例为 78.55%，占公司总股本比例为 8.09%。 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 4.58%。温伟先生累计质押公司股份 5,300,000 股，占其持 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The innovative drug concept stocks are showing strength, with Seer Medical hitting the daily limit up [1] - Guangsheng Tang increased by over 7%, indicating positive market sentiment [1] - Other companies such as Yuandong Biological, Huahai Pharmaceutical, Zhaoyan New Drug, and Enhua Pharmaceutical also experienced upward movement [1]

Group 1 - The core viewpoint of the news is that Sely Medical's stock has increased by 5.02%, reaching a price of 29.89 yuan per share, with a trading volume of 3.09 billion yuan and a turnover rate of 5.02%, resulting in a total market capitalization of 62.81 billion yuan [1] - Sely Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Sely Medical's main business is as follows: IVD business accounts for 39.91%, SPD business accounts for 38.01%, and pure sales account for 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under Caitong Fund ranks among the top shareholders. Caitong Advantage Industry Rotation Mixed A (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 920,100 yuan [2] - Caitong Advantage Industry Rotation Mixed A (011201) was established on February 9, 2021, with a latest scale of 536 million yuan. Year-to-date return is 27.92%, ranking 2916 out of 8174 in its category; the one-year return is 47.03%, ranking 3325 out of 7981; and since inception, it has a loss of 22.16% [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.45% on September 9, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3807.29, down 0.51%, while the Shenzhen Component Index closed at 12510.6, down 1.23% [1] Stock Performance - The top performer in the pharmaceutical sector was Baiyang Pharmaceutical, which saw a closing price of 31.03 with a gain of 6.67% and a trading volume of 166,100 shares, amounting to 505 million yuan [1] - Saily Medical had a significant decline, closing at 27.60 with a drop of 4.13% and a trading volume of 216,000 shares, totaling 609 million yuan [2] - Other notable stocks included Yingtai Group, which rose by 0.77%, and Dacelin, which saw a minor increase of 0.11% [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 215 million yuan from institutional investors, while retail investors contributed a net inflow of 168 million yuan [2] - The data indicates that retail investors were more active in the market compared to institutional investors, as evidenced by the net inflow figures [2] Individual Stock Capital Flow - Baiyang Pharmaceutical had a net inflow of 26.03 million yuan from institutional investors, while it experienced a net outflow of 17.86 million yuan from retail investors [3] - Nanjing Pharmaceutical saw a net inflow of 7.48 million yuan from institutional investors, but a net outflow of 6.85 million yuan from retail investors [3] - The overall trend shows that while some stocks attracted institutional interest, others faced selling pressure from retail investors [3]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]

Company Overview - Seer Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004. It was listed on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, as well as the agency, research, production, and sales of in vitro diagnostic products [2]. Business Segmentation - The revenue composition of Seer Medical is as follows: IVD business accounts for 39.91%, SPD business for 38.01%, and pure sales for 22.08% [2]. Financial Performance - For the first half of 2025, Seer Medical reported a revenue of 584 million yuan, a year-on-year decrease of 40.20%. The net profit attributable to shareholders was -56.12 million yuan, representing a year-on-year decrease of 1075.89% [2]. Stock Performance - On September 4, Seer Medical's stock price fell by 2.02%, trading at 29.07 yuan per share, with a total market capitalization of 6.109 billion yuan. The stock has increased by 302.63% year-to-date, but has seen a decline of 12.18% over the last five trading days [1]. Trading Activity - Seer Medical has appeared on the trading leaderboard 37 times this year, with the most recent appearance on August 26, where it recorded a net buy of 146 million yuan. The total buy amounted to 489 million yuan, accounting for 18.85% of total trading volume, while total sales reached 343 million yuan, making up 13.22% of total trading volume [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Seer Medical was 45,700, a decrease of 1.94% from the previous period. The average circulating shares per person increased by 1.97% to 4,180 shares [2]. Dividend History - Since its A-share listing, Seer Medical has distributed a total of 27.0741 million yuan in dividends, with no dividends paid in the last three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Caifeng Advantage Industry Rotation Mixed Fund (011201), which held 643,400 shares, marking it as a new shareholder [3].

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.1% on September 2, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Yifeng Pharmacy (603939) saw a significant increase of 3.87%, closing at 24.42 with a trading volume of 272,000 shares and a turnover of 656 million [1] - First Pharmaceutical (600833) rose by 3.70%, closing at 15.13 with a trading volume of 471,400 shares and a turnover of 736 million [1] - Saily Medical (603716) led the decline with a drop of 8.89%, closing at 30.55, with a trading volume of 434,900 shares and a turnover of 1.351 billion [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 384 million from institutional investors, while retail investors experienced a net inflow of 288 million [2] - The data indicates that speculative funds had a net inflow of approximately 95.77 million [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 24.77 million from institutional investors, but a net outflow of 34.79 million from retail investors [3] - Nanjing Pharmaceutical (600713) experienced a net inflow of 19.98 million from institutional investors, with a net outflow of 32.21 million from retail investors [3] - People's Tongtai (600829) had a net inflow of 16.78 million from institutional investors, but a net outflow of 14.47 million from retail investors [3]